← Ecosystem map
MUVON Therapeutics AG
Develops autologous muscle-cell therapy; initial indication is stress urinary incontinence in women.
At a glance
- What it offers
- Biotech
- Primary health focus
- Pelvic Floor Health
- Company stage
- Pilot / Validation
About
Need addressed
Pelvic health / incontinence
Organisation’s contribution
Direct clinical women's-health indication with platform potential beyond women.
Women’s health focus
Women’s Health Core
Primary health area
Pelvic Floor HealthAdditional health area
Urogynecology